Clinical Scorecard: Genetic Immune Dysregulation with Hepatic Manifestations: Challenges in Targeted Therapy versus Hematopoietic Stem Cell Transplantation for GIMAP5 Deficiency
At a Glance
Category
Detail
Condition
GIMAP5 deficiency (GISELL disease)
Key Mechanisms
Biallelic loss-of-function mutations in GIMAP5 lead to altered immunity and vascular homeostasis.
Target Population
Pediatric patients with GIMAP5 deficiency.
Care Setting
Pediatric care, including specialized immunology and hematology.
Key Highlights
GIMAP5 deficiency results in severe immune dysregulation and hepatic manifestations.
Clinical features include autoimmune cytopenias, severe viral infections, and liver anomalies.
Targeted therapy with sirolimus has shown efficacy in managing symptoms.
Hematopoietic stem cell transplantation poses significant risks due to vascular fragility.
The condition is characterized by unique vascular remodeling in the liver.
Guideline-Based Recommendations
Diagnosis
Clinical exome sequencing and flow cytometric immunophenotyping are recommended for diagnosis.
Management
Immunomodulation with mTOR inhibitors like sirolimus is suggested for symptom management.
Monitoring & Follow-up
Regular monitoring of liver function and immune status is essential.
Risks
Hematopoietic stem cell transplantation may not halt progression of portal hypertension and carries significant mortality risks.
Patient & Prescribing Data
Pediatric patients diagnosed with GIMAP5 deficiency.
Sirolimus has been effective in achieving sustained clinical remission of cytopenias.
Clinical Best Practices
Consider precision medicine approaches before definitive interventions.
Evaluate the risk-benefit profile of HSCT in patients with vascular fragility.
by Mattia Moratti, Michele La Manna, Lucia Colucci, Cristina Cifaldi, Silvia Di Cesare, Gioacchino Andrea Rotulo, Beatrice Rivalta, Donato Amodio, Andrea Pietrobattista, Andrés Caballero-Oteyza, Elisabetta Lembo, Chiara Passarelli, Emma Concetta Manno, Michele Proietti, Gigliola Di Matteo, Giuseppe Palumbo, Caterina Cancrini
